A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Janssen Research & Development, LLC
ClinicalTrials.gov Identifier:
First received: June 7, 2011
Last updated: January 25, 2016
Last verified: January 2016
The primary purpose of this study is to evaluate the efficacy and safety of 2 maintenance regimens of ustekinumab administered subcutaneously to patients with moderately to severely active Crohn's disease who responded to treatment with intravenous ustekinumab in studies CNTO1275CRD3001 and CNTO1275CRD3002, compared to subcutaneously administered placebo.

Condition Intervention Phase
Crohn's Disease
Inflammatory Bowel Disease
Drug: Placebo
Drug: Ustekinumab
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease

Resource links provided by NLM:

Further study details as provided by Janssen Research & Development, LLC:

Primary Outcome Measures:
  • Clinical remission [ Time Frame: at Week 44 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Remission in patient subgroups such as those in remission at Week 0 or those who previously failed TNF-antagonists (ie, patients entering from study CNTO1275CRD3001) [ Time Frame: at Week 44 ] [ Designated as safety issue: No ]
  • Clinical response [ Time Frame: at Week 44 ] [ Designated as safety issue: No ]
  • Corticosteroid-free remission [ Time Frame: at Week 44 ] [ Designated as safety issue: No ]

Enrollment: 1316
Study Start Date: September 2011
Estimated Study Completion Date: November 2019
Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 001

Placebo Responders to ustekinumab:

Form=solution for injection route=Subcutaneous use. One SC injection q4w

Drug: Placebo
Responders to ustekinumab: Form=solution for injection, route=Subcutaneous use. One SC injection q4w
Experimental: 002

Ustekinumab Responders to ustekinumab:

Form=solution for injection route=Subcutaneous use. One SC injection q12w

Drug: Ustekinumab

Responders to ustekinumab:

Form=solution for injection, route=Subcutaneous use. One SC injection q12w

Experimental: 003
Ustekinumab Responders to ustekinumab: type=1 unit=mg number=90 form=solution for injection route=Subcutaneous use. One SC injection q8w
Drug: Ustekinumab
Responders to ustekinumab: type=1, unit=mg, number=90, form=solution for injection, route=Subcutaneous use. One SC injection q8w
Experimental: 004
Ustekinumab Nonresponders to IV induction ustekinumab: type=1 unit=mg number=90 form=solution for injection route=Subcutaneous use. One SC injection at Week 0 if then respond one SC injection q8w
Drug: Ustekinumab
Nonresponders to IV induction ustekinumab: type=1, unit=mg, number=90, form=solution for injection, route=Subcutaneous use. One SC injection at Week 0
Experimental: 005
Ustekinumab Nonresponders to IV placebo: type=1 unit=mg number=130 form=solution for injection route=Intravenous use. One IV administration at Week 0 if then respond one SC injection ustekinumab 90 mg at Week 8 and then q12w
Drug: Ustekinumab
if then respond, one SC injection q8w

Detailed Description:

The main purpose of this study is to determine whether additional ustekinumab treatment is beneficial in patients with moderately to severely active Crohn's disease who initially had a clinical response to IV ustekinumab in one of the 2 initial induction studies (the CNTO1275CRD3001 ["UNITI-1"] or CNTO1275CRD3002 ["UNITI-2"] induction studies). The maintenance treatment will be injections in the skin (given subcutaneously, or "SC") of 90 mg ustekinumab either every 8 weeks or 12 weeks, and the effects (both the benefits and any side effects or adverse events) will be compared to SC placebo injections (otherwise identical except without ustekinumab). Patients who responded to IV ustekinumab in the UNITI-1 or UNITI-2 induction studies will be put into one of these 3 groups by chance (randomly, like rolling dice). The study will be double-blinded (so that neither patients nor study personnel know the identity of the assigned treatment). Patients who are randomized to either SC placebo or 90mg ustekinumab SC every 12 weeks who experience worsening in their Crohn's Disease symptoms (per the study loss of response criteria) will have their treatment adjusted so that they will instead start to receive 90mg ustekinumab SC every 8 weeks. All patients from the UNITI-1 or UNITI-2 studies (in addition to the patients described above who responded to IV ustekinumab) will be eligible to enter this study, provided the Week 8 visit in those trials was completed and study requirements are still met. Patients who are not in clinical response to IV placebo or ustekinumab in UNITI-1 or UNITI-2 will receive both IV and SC study agent at the first visit of this study (week 0). Patients previously receiving IV placebo will receive ustekinumab 130 mg IV at week 0 (and SC placebo), and patients previously receiving IV ustekinumab will receive 90 mg ustekinumab SC at week 0 (as well as IV placebo). If these patients are in clinical response 8 weeks later, they will receive 90 SC ustekinumab at that week8 visit, and will continue to receive ustekinumab throughout the rest of the study (provided they otherwise remain eligible). Patients in clinical response to IV placebo induction dosing will continue to receive SC placebo. The main part of this study, also called the maintenance portion, will last 44 weeks. After week 44, all participants who are continuing to do well will be eligible to continue to receive study agent in the second part of the study, a long term extension where the study agent will continue to be administered up to week 252. Participants who discontinue study agent, either during the study, or after week 252, will be asked to return for a final safety follow-up visit 20 weeks after they last received study agent.

Patients in response to IV ustekinumab will be randomized to receive either placebo (Group 1), Ustekinumab 90 mg SC every 12 weeks (Group 2), or Ustekinumab 90mgSC every 8 weeks (Group 3). If patients in Groups 1 or 2 lose response, they will cross over to receive ustekinumab 90mg every 8 weeks. Other populations (nonresponders to prior IV ustekinumab or IV placebo) will receive ustekinumab at Week0 (either 90mg SC or 130mg IV, respectively) and continue SC ustekinumab if in response at Week8


Ages Eligible for Study:   18 Years to 99 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who received study agent at the start of study CNTO1275CRD3001 or CNTO1275CRD3002 and completed the Week 8 visit. Exclusion Criteria:
  • Patients who underwent a Crohn's disease-related surgery since the start of induction study CNTO1275CRD3001 or CNTO1275CRD3002
  • Patients who started a protocol prohibited medication since the start of studies CNTO1275CRD3001 and CNTO1275CRD3002
  • Patients with protocol-specified changes to their concomitant medications due to Crohn's disease (due to lack of efficacy) since the start of studies CNTO1275CRD3001 and CNTO1275CRD3002
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01369355

  Hide Study Locations
United States, Arizona
Tucson, Arizona, United States
United States, California
La Jolla, California, United States
Los Angeles, California, United States
San Carlos, California, United States
San Diego, California, United States
Santa Monica, California, United States
United States, Colorado
Lone Tree, Colorado, United States
United States, Connecticut
New Haven, Connecticut, United States
United States, Florida
Boca Raton, Florida, United States
Gainesville, Florida, United States
Jacksonville, Florida, United States
Naples, Florida, United States
Weston, Florida, United States
Winter Park, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
Decatur, Georgia, United States
Macon, Georgia, United States
United States, Idaho
Idaho Falls, Idaho, United States
United States, Illinois
Chicago, Illinois, United States
Evanston, Illinois, United States
United States, Iowa
Clive, Iowa, United States
United States, Kansas
Pratt, Kansas, United States
United States, Kentucky
Crestview Hills, Kentucky, United States
Lexington, Kentucky, United States
Louisville, Kentucky, United States
United States, Louisiana
Baton Rouge, Louisiana, United States
New Orleans, Louisiana, United States
United States, Maryland
Baltimore, Maryland, United States
Chevy Chase, Maryland, United States
Towson, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
Worcester, Massachusetts, United States
United States, Michigan
Ann Arbor, Michigan, United States
Chesterfield, Michigan, United States
Novi, Michigan, United States
Troy, Michigan, United States
Ypsilanti, Michigan, United States
United States, Minnesota
Rochester, Minnesota, United States
United States, Mississippi
Jackson, Mississippi, United States
Ocean Springs, Mississippi, United States
United States, Missouri
Columbia, Missouri, United States
Lees Summit, Missouri, United States
Urbana, Missouri, United States
United States, Nevada
Las Vegas, Nevada, United States
United States, New Hampshire
Lebanon, New Hampshire, United States
United States, New Jersey
Marlton, New Jersey, United States
United States, New York
Great Neck, New York, United States
New York, New York, United States
Poughkeepsie, New York, United States
Rochester, New York, United States
United States, North Carolina
Chapel Hill, North Carolina, United States
Charlotte, North Carolina, United States
Raleigh, North Carolina, United States
United States, Ohio
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Mentor, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Oregon
Bend, Oregon, United States
Portland, Oregon, United States
United States, Pennsylvania
Hershey, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
United States, South Carolina
Columbia, South Carolina, United States
North Charleston, South Carolina, United States
United States, Tennessee
Nashville, Tennessee, United States
United States, Texas
Austin, Texas, United States
Grapevine, Texas, United States
Houston, Texas, United States
Tyler, Texas, United States
United States, Utah
Salt Lake City, Utah, United States
United States, Virginia
Charlottesville, Virginia, United States
Chesapeake, Virginia, United States
Virginia Beach, Virginia, United States
United States, Washington
Seattle, Washington, United States
United States, Wisconsin
Madison, Wisconsin, United States
Adelaide, Australia
Bedford Park, Australia
Box Hill, Australia
Central Queensland M C, Australia
Concord, Australia
Garran, Australia
Liverpool, Australia
Malvern, Australia
Parkville, Australia
Innsbruck, Austria
Wien, Austria
Brussel, Belgium
Leuven, Belgium
Liege, Belgium
Goiânia, Brazil
Porto Alegre, Brazil
Rio De Janeiro, Brazil
São Paulo, Brazil
Pleven, Bulgaria
Rousse, Bulgaria
Sofia, Bulgaria
Varna, Bulgaria
Canada, Alberta
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Canada, British Columbia
Vancouver, British Columbia, Canada
Canada, Manitoba
Brandon, Manitoba, Canada
Canada, Ontario
Hamilton, Ontario, Canada
Kingston, Ontario, Canada
London, Ontario, Canada
Toronto, Ontario, Canada
Canada, Quebec
Montreal, Quebec, Canada
Saskatoon N/A, Canada
Winnipeg, Canada
Rijeka, Croatia
Zagreb, Croatia
Czech Republic
Hradec Kralove, Czech Republic
Usti Nad Labem, Czech Republic
Herlev, Denmark
Silkeborg, Denmark
Lille, France
Marseille, France
Paris, France
Pessac, France
Reims, France
Rouen, France
Toulouse, France
Vandoeuvre Les Nancy, France
Berlin, Germany
Erlangen, Germany
Frankfurt, Germany
Freiburg, Germany
Halle, Germany
Hamburg, Germany
Hannover, Germany
Haßloch, Germany
Heidelberg, Germany
Jena, Germany
Kiel, Germany
Lÿneburg, Germany
Mannheim, Germany
München, Germany
Münster, Germany
Regensburg, Germany
Stade, Germany
Ulm, Germany
Budapest, Hungary
Budapest N/A, Hungary
Békéscsaba, Hungary
Debrecen, Hungary
Mosonmagyarovar, Hungary
Pecs, Hungary
Szekesfehervar, Hungary
Szeksz Rd N/A, Hungary
Reykjavik, Iceland
Dublin 9, Ireland
Jerusalem, Israel
Kfar Saba, Israel
Petah Tikva, Israel
Ramat-Gan, Israel
Rehovot, Israel
Tel Aviv, Israel
Zerifin, Israel
Chikushino, Japan
Fukuoka, Japan
Hachioji, Japan
Hamamatsu, Japan
Hirosaki, Japan
Hiroshima, Japan
Kagoshima, Japan
Nishinomiya, Japan
Ohtsu, Japan
Oita, Japan
Osaka, Japan
Sakura, Japan
Sapporo, Japan
Sendai, Japan
Suita-Shi, Japan
Tokyo, Japan
Tsu, Japan
Uruma, Japan
Yokkaichi, Japan
Yokohama, Japan
Yokosuka, Japan
Korea, Republic of
Daegu, Korea, Republic of
Gyeonggi-Do, Korea, Republic of
Seoul, Korea, Republic of
Amsterdam, Netherlands
Maastricht, Netherlands
Rotterdam, Netherlands
New Zealand
Auckland, New Zealand
Christchurch, New Zealand
Dunedin, New Zealand
Grafton, New Zealand
Hamilton, New Zealand
Hastings, New Zealand
Plenty, New Zealand
Elblag, Poland
Krakow, Poland
Lodz, Poland
Warszawa, Poland
Russian Federation
Moscow, Russian Federation
Novosibirsk, Russian Federation
Saint-Petersburg, Russian Federation
Belgrade, Serbia
South Africa
Cape Town, South Africa
Cape Town Western Cape, South Africa
Pretoria, South Africa
Somerset West, South Africa
Madrid, Spain
United Kingdom
Birmingham, United Kingdom
Brighton, United Kingdom
Bristol, United Kingdom
Cambridge, United Kingdom
Cardiff, United Kingdom
Exeter, United Kingdom
Gloucester, United Kingdom
Liverpool, United Kingdom
London, United Kingdom
Manchester, United Kingdom
Norwich, United Kingdom
Nottinghamshirecc, United Kingdom
Oxford, United Kingdom
Shropshire, United Kingdom
Southampton, United Kingdom
Sponsors and Collaborators
Janssen Research & Development, LLC
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC
  More Information

Responsible Party: Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT01369355     History of Changes
Other Study ID Numbers: CR018421  CNTO1275CRD3003  2010-022760-12 
Study First Received: June 7, 2011
Last Updated: January 25, 2016
Health Authority: United States: Food and Drug Administration
Austria: Ministry of Health, Pharmaceutical Division
Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment
Bulgaria: Bulgarian Drug Agency
Czech Republic: State Institute for Drug Control
Denmark: Danish Health and Medicines Authority
France: National Agency for the Safety of Medicines and Health Products
Hungary: National Institute of Pharmacy and Nutrition
Ireland: Health Products Regulatory Authority
Italy: Italian Medicines Agency
Netherlands: Medicines Evaluation Board
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Spain: Agencia Española de Medicamentos y Productos Sanitarios
United Kingdom: Danish Health and Medicines Authority
Brazil: Brazilian Health Surveillance Agency
Croatia: Agency for Medicinal Product and Medical Devices
Iceland: Icelandic Medicines Agency
New Zealand: Ministry of Health
Russia: Federal Service on Surveillance in Healthcare
Serbia: Medicines and Medical Devices Agency
South Africa: Medicines Control Council
South Korea: Ministry of Food and Drug Safety
Australia: Department of Health and Ageing Therapeutic Goods Administration
Japan: Pharmaceuticals and Medical Devices Agency
Israel: Israeli Health Ministry Pharmaceutical Administration
Germany: Paul-Ehrlich-Institut

Keywords provided by Janssen Research & Development, LLC:
Stelara, Moderately to severely active Crohn's Disease
IBD, Crohn's

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases

ClinicalTrials.gov processed this record on April 27, 2016